Kornimate/medical-research-clean huggingface dataset:
quantitative real-time ultrasound elastography for characterisation of liver tumors

Conditions: Haemangioma; Metastases; Cholangiocellular Carcinoma; Hepatocellular Carcinoma; Focal Nodular Hyperplasia

Summary: shear wave elastography (swe™) is a quantitative elastography method for measuring tissue stiffness. the difference in stiffness between benign and malignant tumors has been demonstrated by other elastography methods (acoustic radiation force impulse imaging, transient elastography and/or magnetic resonance elastography). the investigators hypothesized that benign liver tumors are softer than malignant liver tumors measured by swe™, allowing differentiation between the two by tumor stiffness expressed in kilopascal (kpa). in this study benign and malignant liver tumors will be evaluated in five groups: 1) hemangioma and 2) focal nodular hyperplasia (fnh) representing the most common benign liver tumors; 3) metastases and 4) cholangiocarcinoma (ccc), both presenting malignant tumors mostly appearing in otherwise healthy liver, and 5) hepatocellular carcinoma (hcc) mostly occurring in cirrhotic liver, which can potentially influence elastographic measurements therefore querying the appropriateness of comparison between tumors in healthy and cirrhotic liver. enrolled patients will undergo transabdominal ultrasonography and swe™ examination. the tumor stiffness will be measured five times for each tumor. additionally, surrounding liver parenchyma stiffness will be measured. the nature of the liver tumor will be defined through a standard diagnostic workup according to current guidelines, including contrast enhanced multi-slice ct, mri and/or cytology/histology, as applicable. in the final analysis the mean tumor stiffness and tumor-parenchyma ratio will be calculated for each group as well as for benign and malignant tumors separately, and cut-off values for the differentiation of various groups will be derived. the clinical value of the method will be appraised based on specificity, sensitivity, positive and negative predictive values, and auc.


Eligibility criteria:
inclusion criteria: * liver tumors detected on us examination of the liver * compliance to the study protocol * signed approval for the diagnostic ultrasound with swe™ exclusion criteria: * haemangioma, focal nodular hyperplasia (fnh), metastasis, cholangiocellular carcinoma (ccc) or hepatocellular carcinoma (hcc) in the proximity of liver capsule (less than 1 cm from the liver surface) * haemangioma, fnh, metastasis, ccc or hcc deep in the lever parenchyma (more than 7 cm away from the surface) * liver tumors other than haemangioma, fnh, metastasis, ccc and hcc * severe hepatitis defined by alanine aminotransferase (alt) values \> 5 x upper limit of normal (uln) * obstructive jaundice * congestive heart failure * pregnancy

Keywords: shear wave elastography haemangiomas metastases hepatocellular carcinoma focal nodular hyperplasia cholangiocellular carcinoma
exercise training in children with congenital heart defect

Conditions: Congenital Heart Disease

Summary: the purpose of this study was to investigate the effects of exercise training on exercise capacity, physical activity (pa), health-related quality of life (hrqol), and the psychosocial factors affecting pa in sedentary congenital heart defect (chd) children and healthy sedentary children. the degree of improvement after exercise training were compared between chd children and healthy sedentary children.

exercise groups took 12-week exercise training, twice in hospital and once at home, using a video game so-called dance dance revolution (ddr), while the control group kept their daily routines.

Eligibility criteria:
inclusion criteria: * children with congenital heart defect s/p repair \> 6 months * sedentary lifestyle exclusion criteria: * unstable hemodynamics * impaired mental and cognition * systemic disease

Keywords: exercise capacity physical activity quality of life
calfactant for direct acute respiratory distress syndrome

Conditions: Respiratory Distress Syndrome, Adult

Summary: this study will determine if administration of an suspension of calfactant, a lung surfactant, intratracheally in patients with direct acute respiratory distress syndrome within 48 hours of requiring mechanical ventilation can decrease the mortality in patients with lethal disease and shorten the course of respiratory failure in patients with sub-lethal disease.

recruitment limited to direct adult respiratory distress syndrome patients who have been intubated \<48 hours. origin of ards must be infectious pneumonia, aspiration of stomach contents, near drowning, smoke inhalation without pulmonary burn, inhaled industrial gas.

Eligibility criteria:
inclusion criteria: 1. respiratory failure due to diffuse infectious pneumonia, aspiration, near drowning, smoke inhalation or industrial gas 2. less than 48 hours of mechanical ventilation 3. informed consent exclusion criteria: 1. pre-existing lung disease 2. coma 3. limited therapeutic goals (do not resuscitate, etc.) 4. failure of another vital organ

Keywords: pneumonia aspiration drowning inhalation
study of adjunctive or monotherapy rapastinel treatment in patients with major depressive disorder (mdd)

Conditions: Depressive Disorder, Major

Summary: multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of mdd.


Eligibility criteria:
inclusion criteria: * completion of lead-in study * adequate therapeutic benefit in the lead-in study to justify continuation of treatment with rapastinel in the judgement of the investigator exclusion criteria: * suicide risk, as determined by meeting any of the following criteria: 1. a suicide attempt within the past year 2. significant risk, as judged by the investigator, based on the psychiatric interview or information collected in the columbia- suicide severity rating scale (c-ssrs) at any visit in the lead-in study 3. montgomery-asberg depression rating scale (madrs) item 10 score ≥ 5 at any visit during participation in the lead-in study where madrs was conducted. * at imminent risk of injuring self or others or causing significant damage to property, as judged by the investigator * females who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during participation * females of childbearing potential and male partners of females of childbearing potential, not using a reliable means of contraception

Keywords: depression
effectiveness of neuromuscular kinesiology taping in plantar fasciitis

Conditions: Fasciitis, Plantar

Summary: one of the pathologies most studied and treated with kinesiotape (kt) is plantar fasciitis (pf). in most of the studies reviewed, it is concluded that there is an improvement in the symptoms of pf when treated with kt: either combined with other therapies or as a single treatment compared to placebo. however, most current studies have limitations because the sample is small, the effect size is small, and the evidence is insufficient or of low quality. in the present work, the aim is to study the effectiveness of kt in pf, and to compare the results with those obtained in a placebo group, which is treated with tape. the researchers will assess the decrease in symptoms prior to performing other definitive treatments. in addition, the variability of the painful symptoms and the durability of the bandage will be studied, in order to determine whether it can be used in the short or long period of time, being able to take it into account and supposing a supplement to the pharmacological treatment.


Eligibility criteria:
inclusion criteria: * people with acute plantar fasciitis with less than 3 months of evolution * who present pain in the fascia both during ambulation and on palpation * ecographic image compatible with plantar fasciitis (\> 4 mm) * the condition has not be previously treated with other treatment exclusion criteria: * condition with no sintomatology
revascularization and valve intervention for ischemic valve disease: revive trial

Conditions: Mitral Valve Insufficiency; Coronary Artery Disease

Summary: ischemic mitral regurgitation (mr) and coronary artery disease is common and associated with significant morbidity and mortality. ischemic mr has been traditionally treated surgically through either valve repair or replacement at the time of concomitant bypass grafting. although patients with ischemic mr represent a heterogeneous group, outcomes for these patients over the intermediate term is poor owing to left ventricle (lv) dysfunction causing mr and the presence of coronary disease, which portends poor survival. there is an emergence of percutaneous therapies to treat mr which have been shown to be a less invasive, safe, and viable approach to treat comorbid patients. the decision to treat ischemic mr either surgically or percutaneously is influenced by the presence of coronary disease and the ability to provide adequate revascularization. mitral valve surgery concomitant to surgical revascularization, however, is associated with a several fold increase in mortality. in fact, the incremental risk increase is further magnified in high-risk patients. we therefore propose a novel prospective study to guide intervention for ischemic mr. patients will be randomized to undergo surgical therapy with either mitral repair/replacement and/or concomitant coronary artery bypass grafting or percutaneous mitral repair, followed by coronary artery bypass grafting.


Eligibility criteria:
inclusion criteria: 1. patients with severe ischemic mitral regurgitation (mr), as defined by the 2017 american society of echocardiography (ase) guidelines for noninvasive evaluation of native valvular regurgitation. 2. presence of reversible myocardial ischemia confirmed by preoperative myocardial viability study using radionuclide imaging. exclusion criteria: 1. patients with mixed mitral valve pathology, including fibroelastic deficiency, rheumatic valve disease, ruptured mitral valve chordae, mitral valve endocarditis. 2. patients with acute ischemic mr, defined as mr caused by papillary muscle infarction and rupture. 3. age \< 18 years. 4. prohibitive surgical risk or contraindications to cardiopulmonary bypass (cpb) as defined by the heart team. 5. need for a concomitant surgical procedure, excluding coronary artery bypass grafting (cabg), tricuspid valve repair, patent foramen ovale (pfo) closure, atrial septal defect (asd) closure and maze procedure. 6. prior mitral valve repair procedure (percutaneous or surgical). 7. leaflet anatomy unsuitable for mitraclip implantation, proper mitraclip positioning on the leaflets or sufficient reduction in mr by the mitraclip.
treadmill training and orthotic use in infants with down syndrome

Conditions: Down Syndrome

Summary: this study determines the effect of orthotic use in combination with treadmill training on the development of gross motor skills and walking onset in infants with down syndrome.

the goal of this study is to determine if orthotic use impacts the development of walking and upright play skills over and above the impact that treadmill training alone has. infants with down syndrome who can pull to stand but not walk will be recruited and assigned to a group that receives treadmill training and orthoses or just treadmill training. the infants are followed monthly until they have one month of walking experience. during the monthly visits, the infants' gross motor development is tested and their upright play behavior is observed. at the end of the study each infants gait is evaluated. we believe that the orthoses will lead to a decreased age at walking onset, an improvement in gait patterns, and an improvement in upright play ability.

Eligibility criteria:
inclusion criteria: * trisomy 21 * able to pull to stand but not walk exclusion criteria: * additional developmental diagnoses * uncorrected vision or hearing impairments * previous orthotic intervention * previous treadmill intervention

Keywords: down syndrome gait motor development orthoses
haloperidol vs. risperidone in the treatment of aggression in psychotic inmates

Conditions: Psychosis; Aggression

Summary: this study examines the efficacy of haldol versus risperdal in the treatment of aggression in psychotic prison inmates. it is hypothsized that risperdal will be more effective in decreasing aggression than haldol.


Eligibility criteria:
inclusion criteria:age 18 or over, psychotic disorder diagnosed on scid, inmate at correctional facility for at least 2 weeks - exclusion criteria: active withdrawal from substances of abuse, non-psychotic individuals, pregnant women, people unable to give informed consent, patients on mood stabilizers -
dietry pattern and lead levels in pregnancy

Conditions: Dietary Habits; Lead Poisoning; Pregnancy Related

Summary: during pregnancy lead crosses the placenta freely and can have adverse effects on the fetus, with the potential for life-long impact on the child. identification of dietary patterns and food groups in pregnancy in relation to measures of lead status could provide a more useful alternative to a nutrient-specific advice to minimise fetal exposure to lead during pregnancy. the aim is to evaluate whether dietary patterns and food groups are associated with blood lead concentrations in pregnancy.

whole blood samples were collected from pregnant women enrolled in the avon longitudinal study of parents and children observational birth cohort study and were analysed for lead. dietary pattern scores were derived from principal components analysis of a food frequency questionnaire. associations of quartiles of dietary pattern scores, and of food groups categorised by frequency of consumption, with the likelihood of blood lead concentration (b-pb) ≥5 µg/dl will be identified with adjusted logistic regression (n=2167).

Eligibility criteria:
inclusion criteria: enrolled in alspac, pregnant - exclusion criteria: not enrolled in alspac, not pregnant -

Keywords: dietary patterns pregnancy woman diet lead alspac
a multicenter, cross-sectional study on the quality of life in long-term survival esophageal cancer patients after radical radiochemotherapy/radiotherapy

Conditions: Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival

Summary: this study is a multicenter cross-sectional survey of esophageal cancer patients who underwent radical chemoradiotherapy/radiotherapy from july 2017 to july 2020 in various medical centers, and who survived without disease progression at the time of the survey. the purpose of this study is to evaluate the current quality of life, as well as the incidence of long-term toxic side effects, nutritional status, and psychological status of esophageal cancer patients cured by radiotherapy.


Eligibility criteria:
inclusion criteria: * voluntarily accept this survey and research; * the age at the time of radiotherapy is between 18-75 years old, and the age at the time of investigation is\<80 years old; * histologically confirmed esophageal squamous cell carcinoma without undergoing surgical resection; * received radical chemoradiotherapy/radiotherapy from july 2017 to july 2020, currently alive and without disease progression; * radiotherapy dose ≥ 45gy. exclusion criteria: * patients who do not cooperate with this survey; * patients who have died at the time of investigation; * patients who experience tumor progression within the time frame from the end of radiotherapy to receiving this survey; * patients diagnosed with other malignant tumors within the time frame from the end of radiotherapy to receiving this survey; * patients with incorrect contact information and missing visits
the impact of anemia of chronic disease on chronic obstructive pulmonary disease patients

Conditions: Anemia; COPD

Summary: hypothesis: the first part of the study is a survey on the prevalence of anemia of chronic disease (acd) among copd patients. the 2nd and 3rd part will test 2 null hypotheses (ho): 1.serum inflammatory markers and plasma erythropoietin do not differ between copd patients with and without acd and 2. exercise capacity does not differ between copd patients with and without acd. rationale-aim: acd is an immune driven disorder, developing in subjects suffering from chronic inflammatory diseases. copd is a disorder very likely to be associated to acd due to its systemic inflammatory dimension. currently, data on the prevalence of acd and on the level of inflammatory markers which are implicated in the pathogenesis of acd in copd subjects are limited and controversial. furthermore, there is no data on the effect of acd on exercise capacity of copd subjects. based to the aforementioned, this study has three goals: 1. to determine the prevalence and the epidemiologic characteristics of acd in a population of clinical stable copd patients 2. to investigate whether the levels of serum inflammatory markers and of plasma erythropoietin differ between copd patients with acd and without acd 3. to determine potential differences regarding the aerobic exercise capacity between these two groups, using the cardiopulmonary exercise testing (cpet).


Eligibility criteria:
inclusion criteria: * 1st part of the study: * copd clinically stable (patients with post-bronchodilation fev1/fvc \<0.7 and no acute exacerbations, hospital admissions or treatment changes in the last 3 months). * 2nd and 3rd part: * as above. exclusion criteria: * 1st part of the study: * history of asthma, * history of respiratory infection in the last 3 months * 2nd and 3rd part: as above and additionally: * history of malignancy or haematologic disorder * acute or chronic inflammatory disease * systematic or autoimmune disorder * thyroid disease * liver cirrhosis * heart failure (ejection fraction \<55%) * history of gastrointestinal or other hemorrhage * renal failure (gfr\<60 ml/min/1.73m2) * blood transfusion in the last 4 months * administration of cortisone in the last month * pregnancy * mental impairment * medical conditions which are contraindications to exercise testing, such as: * acute myocardial infarction (in the last 6 months) * unstable angina * left main coronary stenosis or its equivalent * syncope * symptomatic severe aortic stenosis or other moderate stenotic valvular disease * uncontrolled arrhythmias causing symptoms * acute pulmonary embolus or pulmonary infarction * thrombosis of lower extremities * suspected dissecting aneurysm * pulmonary oedema * room air desaturation at rest \<85% * severe untreated arterial hypertension at rest (\>200 mmhg systolic, \>120 mmhg diastolic) * high degree atrioventricular block * hypertrophic cardiomyopathy and * orthopedic impairment that compromises exercise performance

Keywords: copd anemia exercise cytokines erythropoietin
study to investigate the efficacy and tolerability of azd1446 in adult adhd patients.

Conditions: Adult ADHD

Summary: the purpose of this study is to determine whether 2 weeks of treatment with azd1446 compared to placebo improves adhd symptoms and is well tolerated.


Eligibility criteria:
inclusion criteria: * a confirmed diagnosis of adhd * patient understands and is willing to comply with all study requirements * adults between the ages of 18-65 inclusive exclusion criteria: * current psychiatric disorder other than adhd * previous randomization into this study * women with a positive pregnancy test

Keywords: adult adhd
amylin and cgrp head to head provocation in migraine without aura patients

Conditions: Migraine Without Aura

Summary: amylin and calcitonin gene related peptide (cgrp) are related to the same peptide family. both share 16 out of 37 amino acids and can activate each others receptor. cgrp is implicated in migraine pathophysiology but the role of amylin and its receptor in migraine is not fully clarified.

amylin is a peptide hormone that binds to a g-protein coupled receptor (gpcr). amylin was originally found in the pancreas (beta cell of islets of langerhans) but also shown to be present in the trigeminal ganglion, hind horn ganglia and perivascular nerve fibers. amylin has many similarities with cgrp. amylin and cgrp share 16 out 37 amino acids. both peptides can activate the amylin 1 subtype (amy1)receptor with high affinity and reported to have more similar physiological and pharmacological effects. in addition, both peptides increase the intracellular concentration of cyclic amp (camp) which has a central role in migraine pathophysiology. the aim of the study is pin point the role of amylin and amylin receptor compare to cgrp in migraine pathophysiology.

Eligibility criteria:
inclusion criteria: * migraine patients meeting international headache society (ihs) criteria for migraine without aura of both sexes, 18-60 year, 50-100 kg. * fertile women should use safe contraception. fertile women do not include hysterectomized women or women who are postmenopausal for at least 2 years. safe contraception includes either intra uterine device (iud), birth control pills, surgical sterilization of the woman or depot progestogen. exclusion criteria: * tension type headache for more than 5 days the month on average in the last year. * all other primary headaches . * headache later than 48 hours before trial start. * daily intake of any medicine other than oral contraception. * ingestion of any form of medicinal product later than 4 times the plasma half-life substance (on trial day), except for oral contraception. * pregnant or breastfeeding women. * headache on the test day or later than 48 hours prior to administration of trial medicine / placebo * migraine within 5 days before the trial date. * ancestral information or clinical signs of (on the day of inclusion): * hypertension (systolic blood pressure\> 150 mmhg and / or diastolic blood pressure\> 100 mmhg) * hypotension (systolic blood pressure \<90 mm hg and / or diastolic blood pressure \<50 mmhg) * cardiovascular disease of all kinds, including cerebrovascular disease. * anamnestic or clinical signs of mental illness or abuse. * patients with glaucoma or prostatic hyperplasia * anamnestic or clinical signs of diseases of any kind such as the investigating physician is considered relevant for participation in the trial.